We have located links that may give you full text access.
Targeted delivery of galunisertib using machine perfusion reduces fibrogenesis in an integrated ex vivo renal transplant and fibrogenesis model.
British Journal of Pharmacology 2023 August 20
BACKGROUND AND PURPOSE: Fibrosis in kidney allografts is a major post-transplant complication that contributes to graft failure. Lately, multiple potent inhibitors of fibrosis-related pathways have been developed such as galunisertib-an inhibitor of the transforming growth factor-beta (TGF-β) signaling pathway. This drug, however, poses risks for adverse effects when administered systemically. Therefore, we devised a new repurposing strategy in which galunisertib is administered ex vivo. We combined machine perfusion and tissue slices to explore the antifibrotic effects of galunisertib in renal grafts.
EXPERIMENTAL APPROACH: Porcine kidneys were subjected to 30 min of warm ischemia, 24 h of oxygenated hypothermic machine perfusion, and 6 h of normothermic machine perfusion with various treatments (i.e., untreated control, TFG-β, galunisertib, or TGF-β+galunisertib; n=8 kidneys per group). To determine whether effects persisted upon ceasing treatment, kidney slices were prepared from respective kidneys and incubated for 48 h.
KEY RESULTS: Galunisertib treatment improved general viability without negatively affecting renal function or elevating levels of injury markers or byproducts of oxidative stress during perfusion. Galunisertib also reduced inflammation and more importantly, reduced the onset of fibrosis after 48 h incubation.
CONCLUSIONS AND IMPLICATIONS: Our findings demonstrate the value of using machine perfusion for administering anti- fibrotic drugs, such as galunisertib, proving it to be an effective example of repurposing.
EXPERIMENTAL APPROACH: Porcine kidneys were subjected to 30 min of warm ischemia, 24 h of oxygenated hypothermic machine perfusion, and 6 h of normothermic machine perfusion with various treatments (i.e., untreated control, TFG-β, galunisertib, or TGF-β+galunisertib; n=8 kidneys per group). To determine whether effects persisted upon ceasing treatment, kidney slices were prepared from respective kidneys and incubated for 48 h.
KEY RESULTS: Galunisertib treatment improved general viability without negatively affecting renal function or elevating levels of injury markers or byproducts of oxidative stress during perfusion. Galunisertib also reduced inflammation and more importantly, reduced the onset of fibrosis after 48 h incubation.
CONCLUSIONS AND IMPLICATIONS: Our findings demonstrate the value of using machine perfusion for administering anti- fibrotic drugs, such as galunisertib, proving it to be an effective example of repurposing.
Full text links
Related Resources
Trending Papers
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
Management of Diverticulitis: A Review.JAMA Surgery 2024 April 18
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app